Literature DB >> 19361750

What is the role for donor natural killer cells after nonmyeloablative conditioning?

Frédéric Baron1, Effie W Petersdorf, Ted Gooley, Brenda M Sandmaier, Mari Malkki, Thomas R Chauncey, David G Maloney, Rainer Storb.   

Abstract

We investigated the impacts of the tempo of early (days 14, 28, and 42) donor T cell and natural killer (NK) cell engraftment, missing recipient killer cell immunoglobulin-like receptor (KIR) ligands, and numbers of donor inhibitory and activating KIR genes on hematopoietic cell transplantation (HCT) outcomes in 282 patients with hematologic malignancies given nonmyeloablative conditioning. Modeling chimerism levels as a continuous linear variable, we found that high early donor T cell chimerism was significantly associated with acute graft-versus-host disease (aGVHD) (P = .01), whereas high donor NK cell chimerism levels had no such association (P = .38). Conversely, high donor NK cell chimerism levels were significantly associated with low relapse risk (P = .0009), whereas no significant association was seen with high donor T cell chimerism (P = .10). The qualitative associations between donor T cell and NK cell chimerism levels and GVHD and relapse did not change after adjustment for the presence of recipient KIR ligands or numbers of donor inhibitory or activating KIR genes. Our data indicate that prompt engraftment of donor NK cells correlated with lessened risks of relapse, but not with GVHD, whereas the converse was true for T cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19361750      PMCID: PMC2735498          DOI: 10.1016/j.bbmt.2009.01.018

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  50 in total

1.  Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.

Authors:  S Giralt; E Estey; M Albitar; K van Besien; G Rondón; P Anderlini; S O'Brien; I Khouri; J Gajewski; R Mehra; D Claxton; B Andersson; M Beran; D Przepiorka; C Koller; S Kornblau; M Kørbling; M Keating; H Kantarjian; R Champlin
Journal:  Blood       Date:  1997-06-15       Impact factor: 22.113

2.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion.

Authors:  J M Goldman; R P Gale; M M Horowitz; J C Biggs; R E Champlin; E Gluckman; R G Hoffmann; S J Jacobsen; A M Marmont; P B McGlave
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

3.  Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants.

Authors:  P J Martin; J A Hansen; B Torok-Storb; D Durnam; D Przepiorka; J O'Quigley; J Sanders; K M Sullivan; R P Witherspoon; H J Deeg
Journal:  Bone Marrow Transplant       Date:  1988-09       Impact factor: 5.483

4.  Human diversity in killer cell inhibitory receptor genes.

Authors:  M Uhrberg; N M Valiante; B P Shum; H G Shilling; K Lienert-Weidenbach; B Corliss; D Tyan; L L Lanier; P Parham
Journal:  Immunity       Date:  1997-12       Impact factor: 31.745

5.  Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors.

Authors:  N M Valiante; M Uhrberg; H G Shilling; K Lienert-Weidenbach; K L Arnett; A D'Andrea; J H Phillips; L L Lanier; P Parham
Journal:  Immunity       Date:  1997-12       Impact factor: 31.745

6.  The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia.

Authors:  Mark A Cook; Donald W Milligan; Christopher D Fegan; Philip J Darbyshire; Premini Mahendra; Charles F Craddock; Paul A H Moss; David C Briggs
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

7.  Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias.

Authors:  D Maraninchi; E Gluckman; D Blaise; D Guyotat; B Rio; J L Pico; V Leblond; M Michallet; F Dreyfus; N Ifrah
Journal:  Lancet       Date:  1987-07-25       Impact factor: 79.321

8.  Analysis of cytotoxic effector cell function in patients with leukemia or aplastic anemia before and after marrow transplantation.

Authors:  S Livnat; M Seigneuret; R Storb; R L Prentice
Journal:  J Immunol       Date:  1980-01       Impact factor: 5.422

9.  Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

Authors:  Frédéric Baron; Jennifer E Baker; Rainer Storb; Theodore A Gooley; Brenda M Sandmaier; Michael B Maris; David G Maloney; Shelly Heimfeld; Dmitrij Oparin; Eustacia Zellmer; Jerald P Radich; F Carl Grumet; Karl G Blume; Thomas R Chauncey; Marie-Térèse Little
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

10.  The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.

Authors:  A Bishara; D De Santis; C C Witt; C Brautbar; F T Christiansen; R Or; A Nagler; S Slavin
Journal:  Tissue Antigens       Date:  2004-03
View more
  28 in total

1.  Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects.

Authors:  Grégory Ehx; Gilles Fransolet; Laurence de Leval; Stéphanie D'Hondt; Sophie Lucas; Muriel Hannon; Loïc Delens; Sophie Dubois; Pierre Drion; Yves Beguin; Stéphanie Humblet-Baron; Frédéric Baron
Journal:  Oncoimmunology       Date:  2017-04-12       Impact factor: 8.110

2.  NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation.

Authors:  Louise E Hogan; Christian Körner; Kristen Hobbs; Camille R Simoneau; Cassandra Thanh; Erica A Gibson; Christine D Palmer; Alisha Pandit; Francisco M Marty; Daniel R Kuritzkes; Stephanie Jost; Jerome Ritz; Timothy J Henrich
Journal:  Blood Adv       Date:  2018-06-26

3.  Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.

Authors:  Maciej Kmieciak; Debasmita Basu; Kyle K Payne; Amir Toor; Adly Yacoub; Xiang-Yang Wang; Lisa Smith; Harry D Bear; Masoud H Manjili
Journal:  J Immunol       Date:  2011-06-13       Impact factor: 5.422

Review 4.  Nonmyeloablative allogeneic hematopoietic cell transplantation.

Authors:  Rainer Storb; Brenda M Sandmaier
Journal:  Haematologica       Date:  2016-05       Impact factor: 9.941

5.  Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  F Baron; M Labopin; D Blaise; L Lopez-Corral; S Vigouroux; C Craddock; M Attal; P Jindra; H Goker; G Socié; P Chevallier; P Browne; A Sandstedt; R F Duarte; A Nagler; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-01-13       Impact factor: 5.483

Review 6.  Immunotherapeutic approaches to treat multiple myeloma.

Authors:  Mieke W H Roeven; Willemijn Hobo; Nicolaas Schaap; Harry Dolstra
Journal:  Hum Vaccin Immunother       Date:  2013-12-11       Impact factor: 3.452

Review 7.  Mesenchymal stromal cells: a new tool against graft-versus-host disease?

Authors:  Frédéric Baron; Rainer Storb
Journal:  Biol Blood Marrow Transplant       Date:  2011-09-29       Impact factor: 5.742

Review 8.  Biology and clinical effects of natural killer cells in allogeneic transplantation.

Authors:  Jonathan E Benjamin; Saar Gill; Robert S Negrin
Journal:  Curr Opin Oncol       Date:  2010-03       Impact factor: 3.645

9.  Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

Authors:  Rainer Storb; Boglarka Gyurkocza; Barry E Storer; Mohamed L Sorror; Karl Blume; Dietger Niederwieser; Thomas R Chauncey; Michael A Pulsipher; Finn B Petersen; Firoozeh Sahebi; Edward D Agura; Parameswaran Hari; Benedetto Bruno; Peter A McSweeney; Michael B Maris; Richard T Maziarz; Amelia A Langston; Wolfgang Bethge; Lars Vindeløv; Georg-Nikolaus Franke; Ginna G Laport; Andrew M Yeager; Kai Hübel; H Joachim Deeg; George E Georges; Mary E D Flowers; Paul J Martin; Marco Mielcarek; Ann E Woolfrey; David G Maloney; Brenda M Sandmaier
Journal:  J Clin Oncol       Date:  2013-03-11       Impact factor: 44.544

10.  Persuading natural killer cells to eliminate bad B cells.

Authors:  Laurence J N Cooper
Journal:  Clin Cancer Res       Date:  2009-07-28       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.